Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table: chemotherapy or targeted therapy agent(s)… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table: chemotherapy or targeted therapy agent(s)… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table: chemotherapy or targeted therapy agent(s)… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with esophageal and GE‐junction carcinoma
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table (subcomparison 1): chemotherapy or… leads to lower overall survival compared with BSC (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes progression‐free survival compared with BSC (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes toxicity compared with BSC (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with esophageal and GE‐junction carcinoma
1 finding from 1 review
Overall survival · palliative participants with AC of the esophagus
Summary of findings table (subcomparison 5): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with AC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 5): chemotherapy or… changes progression‐free survival compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with AC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 5): chemotherapy or… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with AC of the esophagus
1 finding from 1 review
Overall survival · palliative participants with SCC of the esophagus
Summary of findings table (subcomparison 6): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with SCC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 6): chemotherapy or… changes progression‐free survival compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with SCC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 6): chemotherapy or… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with SCC of the esophagus
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to higher overall severe adverse events (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review